Thyroid autoimmunity occurs more frequently in women with breast cancer compared to women with colorectal cancer and controls but it has no impact on relapse-free and overall survival

Oncology Reports

Volumn 18, Issue 6, 2007, Pages 1603-1611

  Jiskra, Jan ^a   Barkmanova, Jaroslava ^a   Limanova, Zdenka ^a   Lánská, Vera ^b   Smutek, Daniel ^a   Potlukova, Eliska ^a   Antosova, Marie ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Antibodies to thyroglobulin; Antibodies to thyroid peroxidase; Breast cancer; Selenium; Thyroid autoimmunity; Thyroid stimulating hormone

Indexed keywords

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BREAST TUMOR; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; REFERENCE VALUE; SURVIVAL; THYROID GLAND;

ADULT; AGED; AGED, 80 AND OVER; AUTOIMMUNE DISEASES; AUTOIMMUNITY; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; REFERENCE VALUES; SURVIVAL ANALYSIS; THYROID GLAND;

EID: 38449122960     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.6.1603     Document Type: Article

References (38)

1. Smyth PP, Smith DF, McDermott EW, Murray MJ, Geraghty JG and O'Higgins NJ: A direct relationship between thyroid enlargement and breast cancer. J Clin Endocrinol Metab 81: 937-941, 1996. (Pubitemid 26083950)
2. Límanová Z, Barkmanová J and Friedmanová Z: The frequent incidence of thyropathies in women with breast carcinoma. Vnitr Lek 44: 76-82, 1998.
3. Smyth PP, Shering SG, Kilbane MT, Murray MJ, McDermot EW, Smith DF and O'Higgins NJ: Serum thyroid peroxidase autoantibodies, thyroid volume and outcome in breast cancer. J Clin Endocrinol Metab 83: 2711-2716, 1998. (Pubitemid 28493765)
4. Gogas J, Kouskos E, Tseleni-Balafouta S, Markopoulos C, Revenas K, Gogas G and Kostakis A: Autoimmune thyroid disease in women with breast carcinoma. Eur J Surg Oncol 27: 626-630, 2001. (Pubitemid 33062168)
5. Turken O, Narin Y, Demirbas S, Onde ME, Sayan O, Kandemir EG, Yaylaci M, et al: Breast cancer in association with thyroid disorders. Breast Cancer Res 5: 110-113, 2003.
6. Jiskra J, Límanová Z, Barkmanová J, Smutek D and Friedmannová Z: Autoimmune thyroid diseases in women with breast cancer and colorectal cancer. Physiol Res 53: 693-702, 2004. (Pubitemid 40065700)
7. Goldman MB, Monson RR and Maloof F: Benign thyroid-diseases and the risk of death from breast-cancer. Oncology 49: 461-466, 1992. (Pubitemid 23003111)
8. Maruchi N, Annegers JF and Kurland LT: Hashimoto's thyroiditis and breast cancer. Mayo Clin Proc 51: 263-265, 1976.
9. Lemmarie M and Baugnet-Mahieu L: Thyroid function in women with breast cancer. Eur J Cancer Clin Oncol 22: 301-307, 1986.
10. Anker GB, Lonning PE, Aakvaag A and Lien EA: Thyroid function in post-menopausal breast cancer patients treated with tamoxifen. Scand J Clin Lab Invest 58: 103-107, 1998. (Pubitemid 28185378)
11. Sarlis NJ, Gourgiotis L, Pucino F and Tolis GJ: Lack of association between Hashimoto thyroiditis and breast cancer: a quantitative research synthesis. Hormones 1: 35-41, 2002.
12. Charalabopoulos K, Kotsalos A, Batistatou A, Charalabopoulos A, Vezyraki P, Peschos D, Kalfakakou V, et al: Selenium in serum and neoplastic tissue in breast cancer: correlation with CEA. Br J Cancer 95: 674-676, 2006. (Pubitemid 44373480)
13. Shah YM, Al-Dhaheri M, Dong Y, Ip C, Jones FE and Rowan BG: Selenium disrupts estrogen receptor (alpha) signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells. Mol Cancer Ther 4: 1239-1249, 2005. (Pubitemid 41149572)
14. Lee SO, Nadiminty N, Wu XX, Lou W, Dong Y, Ip C, Onate SA, et al: Selenium disrupts estrogen signaling by altering estrogen receptor expression and ligand binding in human breast cancer cells. Cancer Res 65: 3487-3492, 2005. (Pubitemid 40524636)
15. Greenwald P: Clinical trials in cancer prevention: current results and perspectives for the future. J Nutr 134: 3507S-3512S, 2004.
16. Dayan CM, Saravan P and Bayly G: Whose normal thyroid function is better - yours or mine? Lancet 3: 353-354, 2002.
17. Kratzsch J, Fiedler GM, Leichtle A, Brugel M, Buchbinder S, Otto L, Sabri O, et al: New reference intervals for thyrotropin and thyroid hormones based on The National Academy of Clinical Biochemistry Citeria and Regular Ultrasonography of the Thyroid Gland. Clin Chem 51: 1480-1486, 2005. (Pubitemid 41060881)
18. Cengiz O, Bozkurt B, Unal B, Yildirim O, Karabeyoglu M, Eroglu A, Kocer B, et al: The relationship between prognostic factors of breast cancer and thyroid disorders in Turkish women. J Surg Oncol 87: 19-25, 2004. (Pubitemid 38880275)
19. Jaeger C, Hatziagelaki E, Petzoldt R and Bretzel RG: Comparative analysis of organ-specific autoantibodies and celiac disease-associated antibodies in type 1 diabetic patients, their first degree relatives and healthy control subjects. Diabetes Care 24: 27-32, 2001. (Pubitemid 32104215)
20. Tunc R, Gonen MS, Acbay O, Hamuryudan V and Yazici H: Autoimmune thyroiditis and anti-thyroid antibodies in primary Sjogren's syndrome: a case-control study. Ann Rheum Dis 63: 575-577, 2004. (Pubitemid 38530203)
21. Dayan CM and Daniels GH: Chronic autoimmune thyroiditis. N Engl J Med 99: 99-107, 1996. (Pubitemid 26240112)
22. Riedel C, Dohan O, De La Vieja A, Ginter CS and Carrasco N: Journey of the iodide transporter NIS: from its molecular identification to its clinical role in cancer. Trends Biochem Sci 26: 490-496, 2001. (Pubitemid 32735450)
23. Cann SA, van Netten JP and van Netten C: Hypothesis: Iodine, selenium and the development of breast cancer. Cancer Causes Control 11: 121-127, 2001.
24. Smyth PA: The thyroid, iodine and breast cancer. Breast Cancer Res 5: 235-238, 2003.
25. Pearce EN, Farwell AP and Braverman LE: Thyroiditis. N Engl J Med 348: 2646-2655, 2003. (Pubitemid 36741593)
26. Zimmermann MB and Kohrle J: The impact of iron and selenium deficiencies on iodide and thyroid metabolism: biochemistry and relevance to public health. Thyroid 12: 867-878, 2002. (Pubitemid 35332991)
27. Prummel MF, Strieder T and Wiersinga WM: The environment and autoimmune thyroid diseases. Eur J Endocrinol 150: 605-618, 2004. (Pubitemid 38786529)
28. Duntas LH, Mantzou E and Koutras DA: Effects of a six-month treatment with selenomethionine in patients with autoimmune thyroiditis. Eur J Endocrinol 148: 389-393, 2003. (Pubitemid 36527409)
29. Thomas BS, Bulbrook RD, Goodman MJ, Russell MJ, Quinlan M, Hayward JL and Takatani O: Thyroid function and the incidence of breast cancer in Hawaiian, British and Japanese women. Int J Cancer 38: 325-329, 1986. (Pubitemid 16022313)
30. Kuijpens JL, Nyklictec I, Louwman MW, Weetman TA, Pop VJ and Coebergh JW: Hypothyroidism might be related to breast cancer in postmenopausal women. Thyroid 15: 1253-1259, 2005. (Pubitemid 41821759)
31. Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M, Hsu L, et al: Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer 103: 1122-1128, 2005. (Pubitemid 40328081)
32. Hercberg A: Hypothyroidism and tumour regression [letter]. N Engl J Med 319: 1351-1352, 1998.
33. Hankinson SE: Endogenous hormones and risk of breast cancer in postmenopausal women. Breast Dis 24: 3-15, 2006.
34. Tworoger SS and Hankinson SE: Prolactin and breast cancer risk. Cancer Lett 243: 160-169, 2006. (Pubitemid 44485858)
35. Schlechte JA: Clinical practice. Prolactinoma. N Engl J Med 349: 2035-2041, 2003.
36. Loi S, Milne RL, Friedlander ML, McCredie MR, Giles GG, Hopper JL and Phillips KA: Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 14: 1686-1691, 2005. (Pubitemid 40995080)
37. Carmichael A: Obesity as a risk factor for the development and poor prognosis of breast cancer. BJOG 7: 333-340, 2006.
38. Breedlove HA, Smith AM, Burk RF, Hill KE and Shapiro CL: Serum selenium measurements in women with early-stage breast cancer with and without chemotherapy-induced ovarian failure. Breast Cancer Res Treat 97: 225-230, 2006. (Pubitemid 43945752)